Collaborative Arrangement, Shares Available For Exchange

No definition available.

Name:	dtil_CollaborativeArrangementSharesAvailableForExchange
Namespace Prefix:	dtil_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Conversion Of Shares, Number Of Days, Volume Weighted Average Price

+ References

No definition available.

+ Details

Name:	dtil_ConversionOfSharesNumberOfDaysVolumeWeightedAveragePrice
Namespace Prefix:	dtil_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number Of Additional Research Programs

+ References

No definition available.

+ Details

Name:	dtil_NumberOfAdditionalResearchPrograms
Namespace Prefix:	dtil_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of premium over the volume-weighted-average-price of the company’s common stock.

+ References

No definition available.

+ Details

Name:	dtil_PercentageOfPremiumOverVolumeWeightedAveragePriceOfCompanysCommonStock
Namespace Prefix:	dtil_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Percentage of value of each additional milestone payment.

+ References

No definition available.

+ Details

Name:	dtil_PercentageOfValueOfEachAdditionalMilestonePayment
Namespace Prefix:	dtil_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Period Of Expiration Of Patents

+ References

No definition available.

+ Details

Name:	dtil_PeriodOfExpirationOfPatents
Namespace Prefix:	dtil_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration, Additional Milestone, Amount

+ References

No definition available.

+ Details

Name:	dtil_RevenueRemainingPerformanceObligationVariableConsiderationAdditionalMilestoneAmount
Namespace Prefix:	dtil_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue, Remaining Performance Obligation, Variable Consideration, Clinical Milestone, Amount

+ References

No definition available.

+ Details

Name:	dtil_RevenueRemainingPerformanceObligationVariableConsiderationClinicalMilestoneAmount
Namespace Prefix:	dtil_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Stock Issued, Price Per Share, Number Of Trading Days Prior To Agreement

+ References

No definition available.

+ Details

Name:	dtil_StockIssuedPricePerShareNumberOfTradingDaysPriorToAgreement
Namespace Prefix:	dtil_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-11

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2

+ Details

Name:	us-gaap_ContractWithCustomerLiability
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8

+ Details

Name:	us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Face (par) amount of debt instrument at time of issuance.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482949/835-30-55-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482900/835-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

+ Details

Name:	us-gaap_DebtInstrumentFaceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(3)(d))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 321
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479536/321-10-50-4

+ Details

Name:	us-gaap_EquitySecuritiesFvNiGainLoss
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12

+ Details

Name:	us-gaap_ProceedsFromSaleOfProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Cash received on stock transaction after deduction of issuance costs.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockConsiderationReceivedOnTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+ References

No definition available.

+ Details

Name:	us-gaap_SaleOfStockPricePerShare
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:perShareItemType
Balance Type:	na
Period Type:	instant

- Details

Name:	srt_CounterpartyNameAxis=dtil_TgLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dtil_PaymentTrancheAxis=dtil_PaymentTrancheOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dtil_PaymentTrancheAxis=dtil_PaymentTrancheTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dtil_ImugeneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dtil_NovartisPharmaAGMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dtil_DiscoveryAndDevelopmentMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=dtil_IECUREMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=dtil_DevelopmentAndLicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

COLLABORATION AND LICENSE AGREEMENTS (Details)								1 Months Ended	2 Months Ended	4 Months Ended	12 Months Ended
COLLABORATION AND LICENSE AGREEMENTS (Details)	Oct. 31, 2025 USD ($)	Jan. 06, 2025 USD ($) $ / shares shares	Aug. 15, 2024 USD ($)	Aug. 14, 2024	Feb. 05, 2024 USD ($) shares	Jan. 07, 2024 USD ($) shares	Aug. 15, 2023 USD ($) research_program	Jul. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2025 USD ($) shares	Dec. 31, 2024 USD ($) shares	Dec. 31, 2025 USD ($)	Dec. 31, 2024 USD ($)
Collaboration and License Agreements [Line items]
Sale of stock, number of shares issued in transaction (in shares) \| shares									0	72,312,592
Revenue recognized											$ 26,300,000
Deferred revenue									$ 0	$ 2,957,000	0	$ 2,957,000
Gain (loss) on changes in fair value of ordinary shares											$ (2,666,000)	258,000
TG License \| License
Collaboration and License Agreements [Line items]
Collaborative arrangement, upfront payments and liabilities		$ 2,500,000				$ 10,000,000.0
Initial milestone						7,500,000
Additional milestone						$ 288,600,000
Sale of stock, number of shares issued in transaction (in shares) \| shares		220,712			97,360
Percentage of premium over the volume-weighted-average-price of the company’s common stock (as a percent)		100.00%			100.00%	100.00%
Number of trading days prior to agreement to determine price per share					30 days
Sale of stock, price per share (in USD per shares) \| $ / shares		$ 11.1660
Percentage of value of each additional milestone payment (as percent)						50.00%
Expiration of patents, period											10 years
TG License \| License \| Payment Tranche One
Collaboration and License Agreements [Line items]
Collaborative arrangement, upfront payments and liabilities					$ 5,250,000
Initial milestone						$ 5,250,000
Additional milestone						3,000,000.0
TG License \| License \| Payment Tranche Two
Collaboration and License Agreements [Line items]
Collaborative arrangement, upfront payments and liabilities					$ 2,250,000
Initial milestone						$ 2,250,000
Shares available for exchange (in shares) \| shares						201,504
Imugene
Collaboration and License Agreements [Line items]
Additional milestone							$ 145,000,000.0
Cash received from sale of business			$ 9,750,000				8,000,000.0
Loan amount							$ 13,000,000.0
Conversion of stock, price, volume weighted average price, number of days				10 days
Number of additional research programs \| research_program							3
Imugene \| License
Collaboration and License Agreements [Line items]
Initial milestone							$ 8,000,000.0
Additional milestone							206,000,000.0
Expiration of patents, period											10 years
Revenue recognized	$ 8,000,000.0										$ 8,000,000.0	0
Imugene \| License \| Payment Tranche One
Collaboration and License Agreements [Line items]
Initial milestone							3,000,000.0
Revenue recognized	3,000,000.0
Imugene \| License \| Payment Tranche Two
Collaboration and License Agreements [Line items]
Initial milestone							$ 5,000,000.0
Revenue recognized	$ 5,000,000.0
Novartis Pharma AG
Collaboration and License Agreements [Line items]
Sale of stock, number of shares issued in transaction (in shares) \| shares								413,581
Percentage of premium over the volume-weighted-average-price of the company’s common stock (as a percent)								20.00%
Sale of stock, price per share (in USD per shares) \| $ / shares								$ 60.30
Conversion of stock, price, volume weighted average price, number of days								10 days
Sale of stock, consideration received								$ 25,000,000.0
Novartis Pharma AG \| Discovery and Development
Collaboration and License Agreements [Line items]
Collaborative arrangement, upfront payments and liabilities								$ 50,000,000.0	$ 0	26,300,000	0	26,300,000
Revenue recognized											26,300,000	6,400,000
Deferred revenue										$ 3,000,000.0		3,000,000.0
iECURE \| Development and License
Collaboration and License Agreements [Line items]
Gain (loss) on changes in fair value of ordinary shares											$ (2,500,000)	$ 0